TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23997364
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tiagabine
Study: 16750452
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg with ezetimibe 10 mg
Study: 16750452
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg alone
Study: 16750452
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg alone
Study: 14636761
Drug: Biobrane-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biobrane-L
Study: 1794819
Drug: Half-strength povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-strength povidone-iodine solution applied for 2 minutes
Study: 6349444
Drug: Rifampicin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (600 mg daily for 6 weeks)
Study: 6349444
Drug: Prednisolone (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (increased dosage)
Study: 24119734
Drug: Sequential interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential interferon alpha‐1b (IFNa‐1b) for 6 months
Study: 24119734
Drug: Telbivudine (LdT)
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telbivudine (LdT) treatment continued for an additional 6 months
Study: 19445374
Drug: Intrauterine fetoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine fetoscopic surgical treatment using a 2-mm endoscope and diode laser fiber, performed under local anesthesia, through a single 3-mm trocard.
Study: 14649785
Drug: Guided self-change
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-change (self-care manual plus eight fortnightly sessions of cognitive behavioural therapy)
Study: 14649785
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (16 weekly sessions)
Study: 8999458
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) administered intravenously at a dose of 50 U/kg body mass
Study: 8434742
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl at a rate of 50 micrograms.h‐1 with additional epidural boluses (25 micrograms) as required
Study: 8434742
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of patient-controlled analgesia and continuous infusion
Study: 8434742
Drug: Nurse-administered analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered analgesia (implied control)
Study: 2957210
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg CM 57755
Study: 2957210
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g CM 57755
Study: 2957210
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g CM 57755
Study: 26211531
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training based physical activity program with weekly discussions on health and quality of life (Mental group)
Study: 20378585
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg ENDD
Study: 20378585
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg ENDD (placebo)
Study: 8784084
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg methimazole daily plus sufficient T4 to maintain TSH in the high-normal range (Group 2)
Study: 8784084
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg methimazole daily plus sufficient T4 to suppress TSH to below 0.6 mIU/L (Group 3)
Study: 1473391
Drug: Succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1 mg/kg i.v. under normal condition (PetCO2 5‐5.5kPa)
Study: 1473391
Drug: Succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1 mg/kg i.v. under hyperventilation (PetCO2 3‐3.5kPa)
Study: 6734304
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of bacampicillin hydrochloride (400 mg)
Study: 6734304
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of bacampicillin hydrochloride (400 mg)
Study: 30609152
Drug: Risperidone (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (continued treatment group)
Study: 31109200
Drug: Placebo (discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (discontinuation group)
Study: 26897490
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (LB) periarticular injection, n = 20
Study: 26897490
Drug: Standard periarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard periarticular injection (ropivacaine, clonidine, Toradol, Epinepherine, saline), n = 18
Study: 20574936
Drug: Hypnoreflexogenous birth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnoreflexogenous birth preparation course
Study: 18271226
Drug: Routine diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine diabetic therapy with acupuncture at specific points (control group)
Study: 15952402
Drug: Neridronate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate (25 mg monthly injection) + Calcium (500 mg daily) + Vitamin D (400 U daily)
Study: 15952402
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg daily) + Vitamin D (400 U daily)
Study: 7596123
Drug: Molsidomine retard
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine retard 8 mg
Study: 1486070
Drug: 3% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% acyclovir ointment and 0.1% betamethasone (Betnesol) drops
Study: 1486070
Drug: Acyclovir ointment
Normalized name: Acyclovir Ointment
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir ointment and matching placebo
Study: 6489764
Drug: Co-dergocrine mesylate
Normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-dergocrine mesylate (Hydergine) 1.5 three times daily
Study: 27729533
Drug: Reading intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reading intervention focusing on the malleability of reading abilities and praising effort; details on dosage and duration not available.
Study: 27729533
Drug: Reading intervention;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading intervention; details on dosage and duration not available.
Study: 22012861
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg kg(‐1) of corrected body weight (Group SUG)
Study: 22012861
Drug: Neostigmine 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.05 mg kg(‐1) of corrected body weight (Group NEO)
Study: 15677779
Drug: PACCTS (Pro‐Active
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACCTS (Pro‐Active Call Center Treatment Support)
Study: 11865416
Drug: Lopinavir/Ritonavir (400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (400/100 mg or 400/200 mg twice daily)
Study: 11865416
Drug: Lopinavir/Ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir plus Nevirapine (200 mg 2x/day) and nucleoside reverse-transcriptase inhibitors
Study: 11865416
Drug: Lopinavir/Ritonavir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir treatment
Study: 7874950
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus NIPSV (n = 21)
Study: 7874950
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n = 20)
Study: 7874950
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus NIPSV (n = 17, subgroup with PaCO2 > 45 mm Hg)
Study: 7874950
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n = 17, subgroup with PaCO2 > 45 mm Hg)
Study: 2211567
Drug: Buspirone 5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 5-10 mg t.i.d. for 6 weeks
Study: 2211567
Drug: Oxazepam 10-20
Normalized name: oxazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 10-20 mg t.i.d. for 6 weeks
Study: 23905374
Drug: Salvianolate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvianolate (200 mg/day) with routine Western medical treatment
Study: 24672935
Drug: Routine Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Western medical treatment (Control)
Study: 19242322
Drug: Unfractioned heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractioned heparin (UFH)
Study: 16542205
Drug: Talinolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol (100 mg daily)
Study: 11522675
Drug: Hypoglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic clamp (blood glucose reduced to 54 mg/dl)
Study: 11522675
Drug: Hyperinsulinemic-euglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic-euglycemic clamp (blood glucose maintained near 100 mg/dl)
Study: 9233903
Drug: Mesterolone (MES)
Normalized name: mesterolone
DrugBank: Mesterolone (DB13587)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesterolone (MES) 100 mg/d
Study: 9233903
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE) 250 mg i.m./21 days
Study: 9233903
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg crystalline testosterone (TPEL) subcutaneously implanted
Study: 8502509
Drug: Ritalin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritalin (0.3 mg/kg per dose)
Study: 3102211
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment group (TG) with CDP of 6 cm water pressure applied at birth by the nasopharyngeal route.
Study: 29938412
Drug: Intravenous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine 2% (Group A)
Study: 18700624
Drug: Haemaccel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemaccel (10 ml/kg intravenously over 10‐15 minutes)
Study: 18700624
Drug: Injection ephedrine
Normalized name: ephedrine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection ephedrine (0.2 mg/kg iv)
Study: 18700624
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no study medication)
Study: 15696985
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate topical gel 1% (CG)
Study: 10548211
Drug: Dalteparin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (20 units/kg bolus, 10 units/kg/hr infusion)
Study: 10548211
Drug: Heparin (2000-5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (2000-5000 units bolus, 10 units/kg/hr infusion, titrated to 70-80 secs aPTT)
Study: 6301320
Drug: Cytomegalovirus immune
Normalized name: cytomegalovirus immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytomegalovirus immune globulin administered before and for 11 weeks after transplantation
Study: 16935718
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT scans
Study: 31664156
Drug: Buffered acidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered acidic saline solution (pH 5.2)
Study: 31664156
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution (pH 6)
Study: 11528262
Drug: Topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dorzolamide
Study: 24560062
Drug: Ranolazine added
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine added to standard-of-care (SoC) treatment
Study: 24560062
Drug: Standard-of-care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SoC) treatment alone
Study: 22834720
Drug: Conservative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative care (IV epidural preload volume of <500 mLs continuing at an hourly rate of 75-100 mL/h)
Study: 22834720
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (epidural preload volume of ≥500 mLs and an hourly rate >125 mL/h)
Study: 19273551
Drug: Antioxidant group
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant group (1 g l-ascorbic acid, 400 IU alpha-tocopherol acetate, 600 mg alpha-lipoic acid in four divided doses)
Study: 12383043
Drug: Fondaparinux sodium
Normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux sodium 10mg + aspirin 975mg
Study: 10369196
Drug: Cyclophosphamide, dipyridamole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, dipyridamole, warfarin
Study: 8537694
Drug: Levosulpiride (L)
Normalized name: L-377202
DrugBank: Levosulpiride (DB16021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (L) 75 mg/day
Study: 8537694
Drug: Metoclopramide (M)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (M) 30 mg/day
Study: 2406218
Drug: Dipivefrin 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipivefrin 0.1% twice daily during the holiday
Study: 2406218
Drug: Timolol therapy
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol therapy restored after holiday
Study: 2406218
Drug: Dipivefrin-treated group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipivefrin-treated group (60 days treatment)
Study: 28241070
Drug: Bisensory‐DBM with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisensory‐DBM with scented cream
Study: 28241070
Drug: Multisensory‐DBM with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory‐DBM with scented cream associated with audiovisual material
Study: 23485514
Drug: Lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic acid (1200 mg/day)
Study: 18163196
Drug: Eptifibatide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (two 180 microg/kg boluses followed by infusion at 2.0 and 1.3 microg/kg/min for 24 and 48 h, respectively)
Study: 18163196
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treated without GP IIb‐IIIa antagonists)
Study: 21455709
Drug: D-cycloserine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (125 mg)
Study: 11159249
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of dextromethorphan given eight hourly
Study: 9773893
Drug: NaCl-NaCitrate beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl-NaCitrate beverage (185 mEq x L(‐1) Na+, 283 mOsm x kg(‐1))
Study: 9773893
Drug: NaCl-NaCitrate beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl-NaCitrate beverage (21.6 mEq x L(‐1) Na+, 365 mOsm x kg(‐1))
Study: 2843314
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg intravenously, followed by a continuous infusion of 10 mg/h)
Study: 28522759
Drug: Ibuprofen (IB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (IB; 10 mg/kg)
Study: 26226987
Drug: High-dose impact-loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose impact-loading (80 jumps per session)
Study: 26226987
Drug: Moderate-dose impact-loading
Normalized name: IMPACT
DrugBank: Topramezone (DB14826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose impact-loading (40 jumps per session)
Study: 14529447
Drug: Dartmouth-regimen combination
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dartmouth-regimen combination chemotherapy
Study: 1090796
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent chemotherapy
Study: 22240497
Drug: Pycnogenol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (200 mg/day) for 8 weeks
Study: 22240497
Drug: Pycnogenol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (200 mg/day)
Study: 18241647
Drug: Yiqing Shuangjie
Normalized name: SODIUM HYPOCHLORITE 6 g in 100 mL TOPICAL LIQUID [(Qiqing) Sodium Hypochlorite Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqing Shuangjie Capsule (treatment group A)
Study: 18241647
Drug: Yiqing Shuangjie
Normalized name: SODIUM HYPOCHLORITE 6 g in 100 mL TOPICAL LIQUID [(Qiqing) Sodium Hypochlorite Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqing Shuangjie Tablet (treatment group B)
Study: 18241647
Drug: Chaihuang Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaihuang Tablet and Yiqing Shuangjie Capsule analogues (control group)
Study: 15763605
Drug: Combination oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oxycodone 5 mg/ibuprofen 400 mg
Study: 9181183
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of synthetic steroids administered orally starting on day 8 of the menstrual cycle (group I)
Study: 9181183
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of synthetic steroids administered orally starting on day 10 of the menstrual cycle (group II)
Study: 11704703
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (dihydropyridine calcium channel blocker)
Study: 11704703
Drug: Nitrendipine monotherapy
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine monotherapy
Study: 8500236
Drug: Enalapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril treatment group
Study: 20519346
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg rhTSH followed by a thyroid dose of 50 Gy
Study: 18580042
Drug: BAS (BlastAssyst
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAS (BlastAssyst system containing L‐glutamine)
Study: 10998833
Drug: Methylcobalamin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin 0.5 mg orally three times a day for 6 months
Study: 10998833
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management (patient education, physical therapy, and medication)
Study: 25654976
Drug: Peganum harmala
Normalized name: TITANIUM DIOXIDE 60 mg in 1 mL / ZINC OXIDE 60 mg in 1 mL TOPICAL CREAM [PHARMACA Natural Mineral Sunscreen SPF-30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peganum harmala L oil, applied 4 drops 3 times a day for 4 weeks
Study: 24727261
Drug: Anti-vascular endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-vascular endothelial growth factor treatment
Study: 24727261
Drug: Pro re
Normalized name: Blistex Pro Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro re nata treatment
Study: 15932376
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (INFP) 200 microg o.d.
Study: 15932376
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (IHFP) 250 microg b.i.d.
Study: 15932376
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of INFP and IHFP
Study: 8739595
Drug: HPMPC (cidofovir)
Normalized name: (S)-HPMPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMPC (cidofovir) at 1 mg/kg
Study: 8739595
Drug: HPMPC (cidofovir)
Normalized name: (S)-HPMPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMPC (cidofovir) at 3 mg/kg
Study: 8739595
Drug: HPMPC (cidofovir)
Normalized name: (S)-HPMPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMPC (cidofovir) at 10 mg/kg
Study: 25738338
Drug: Mucograft (MG;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucograft (MG; a porcine‐derived purified collagen membrane)
Study: 19460106
Drug: 100 mmol
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mmol L(‐1) butyrate
Study: 19460106
Drug: 50 mmol
Normalized name: dibasic potassium phosphate 150 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mmol L(‐1) butyrate
Study: 17712121
Drug: MK‐0557 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐0557 1 mg/d plus sibutramine 10 mg/d
Study: 17712121
Drug: MK‐0557 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐0557 1 mg/d plus orlistat 120 mg TID
Study: 12809960
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg TID
Study: 15117091
Drug: Lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 100 mg
Study: 9543158
Drug: 375 IU
Normalized name: Ascorbic Acid/Biotin/Calcium/Calcium Pantothenate/Cholecalciferol/Chromium/Cyanocobalamin/Folic Acid/Iodine/Magnesium/Manganese/Molybdenum/Niacin/Potassium/Pyridoxine/Riboflavin/Selenium/Thiamine/Vitamin A/Vitamin E/Zinc 300 MG-0.15 MG-150 MG-0.05 MG-375 IU-1 MG-0.012 MG-0.15 MG-200 MG-10 MG-0.15 MG-20 MG-40 MG-150 MG-6 MG-3.9 MG-0.5 MG-3 MG-10500 IU-30 IU-15 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 IU urinary FSH, s.c., as a single injection on Day(LH+14) (group A; n = 11)